Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Jul 2002
Randomized Controlled Trial Comparative Study Clinical TrialUrinary and fecal excretion of topotecan in patients with malignant solid tumours.
The objectives of the study were to determine the pharmacokinetics and routes of excretion of topotecan following intravenous or oral administration to patients with refractory solid tumours. ⋯ Fecal and urinary excretion of unchanged topotecan were the major routes of topotecan elimination. Approximately 28% of the intravenous dose and 43% of the oral dose of topotecan were unaccounted for and eliminated through other routes.